Ligufalimab

Names

[ Name ]:
Ligufalimab

Biological Activity

[Description]:

Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

[In Vitro]

Ligufalimab 结合人 CD47 抗原，EC50 值为 0.078 nM，KD 值为 0.152 nM[1]。 Ligufalimab (0-3000 nM) 不诱导红细胞血凝[1]。 Ligufalimab (0.1、1、10 µg/mL) 以剂量依赖性方式诱导 Raji、Jurkat 和 Ramos 细胞的吞噬作用[1]。

[In Vivo]

Ligufalimab(0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model) 抑制小鼠肿瘤生长[1]。 Animal Model: SCID/Beige mice (Raji xenograft model, MDA-MB-231 xenograft model)[1] Dosage: 0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model Administration: I.v. Result: Inhibited tumor growth with the tumor inhibition rate of 88.56%, 63.78% at 1, 0.1 mg/kg.

[References]

[1]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022 Nov;10(11):e005517.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.